Fig. 6 | Signal Transduction and Targeted Therapy

Fig. 6

From: Targeting epigenetic and posttranslational modifications regulating ferroptosis for the treatment of diseases

Fig. 6

Epigenetic modification of ferroptosis by m6A in cancer. ALKBH5 AlkB homolog 5, ACSL3 acyl-CoA synthetase long-chain family member 3, BC breast cancer, CBS cystathionine-beta-synthase, FSP1 ferroptosis suppressor protein 1, FTH1 ferritin heavy chain 1, FTO fat mass and obesity-associated protein, GBM glioblastoma, GC gastric cancer, HCC hepatocellular carcinoma, GPX4 glutathione peroxidase 4, HDLBP high-density lipoprotein-binding protein, HPSCC hypopharyngeal squamous cell carcinoma, IGF2BP1 Insulin-like growth factor 2 mRNA binding protein 1, IGF2BP2 Insulin-like growth factor 2 mRNA binding protein 2, METTL3 methyltransferase-like protein 3, METTL14 methyltransferase -like 14, METTL16 methyltransferase-like 16, NKAP NF-κB activating protein, NPC nasopharyngeal carcinoma, NSCLC non-small cell lung carcinoma, SFPQ splicing factor proline and glutamine-rich, SLC3A2 solute carrier family 3 member 2, YTHDC2 YTH domain containing 2, YTHDF1 YTH N6-methyladenosine RNA binding protein 1, YTHDF2 YTH N6-methyladenosine RNA binding protein 2, YTHDC2 YTH domain containing 2

Back to article page